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Abstract In India, Adenanthera pavonina is traditionally
used in the treatment of diabetes mellitus and lipid
disorders. In the present study, the antihyperglycaemic
and lipid lowering effect of Adenanthera pavonina seed
aqueous extract (APSAE) was evaluated using strepto-
zotocin induced diabetes in rats. Streptozotocin was
given at the dose of 55 mg/kg, i.p. After induction of
diabetes, APSAE was administered for 30 days p. o.
and simultaneously different biochemical parameters like
plasma glucose, HbA1c, serum triglyceride, cholesterol,
LDL-cholesterol and HDL-cholesterol were estimated.
Diabetic control showed significant increase (P<0.01)
in plasma glucose, serum triglyceride, cholesterol,
LDL-cholesterol and significant decrease (P<0.01) in
serum HDL-cholesterol and HbA1c. Treatment with
APSAE showed significant reduction (P<0.01) in plas-
ma glucose when compared with diabetic control. The
elevated levels of serum triglyceride and cholesterol
levels were significantly reduced (P<0.01) by APSAE.
APSAE treatment for 30 days showed significant de-
crease in serum LDL-cholesterol (P<0.01) and signifi-
cant increase in serum HDL cholesterol level (P<0.01).
Moreover, diabetic control there was significant decrease
in HbA1c which was significantly increased (P<0.05)
by treatment with APSAE. Hence, from the result
obtained in the present study it can be confirmed that
Adenanthera pavonina has the potential to treat diabetes
condition and associated lipid disorders.
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Introduction
Diabetes mellitus (DM) is a chronic disease caused by
inherited or acquired deficiency in insulin secretion and
by decreased responsiveness of the organs to secreted
insulin (Matsui et al. 2007). DM is currently one of the
most costly and burdensome chronic diseases and is a
condition that is increasing in epidemic proportions
throughout the world (King et al. 1998). Diabetes
affects about 5 % of the global population (WHO tra-
ditional medicine strategy 2005) and the management of
diabetes without any side effects is still a challenge to
the medical system (Chakraborty and Rajagopalan 2002;
Kameswararao et al. 2003). Renewed attention in recent
decades to alternative medicines and natural therapies
has stimulated a new wave of research interest in tradi-
tional practices. The plant kingdom has become a target
for the search for new drugs and biologically active
“lead” compounds (Evans 1996). Ethno botanical infor-
mation indicates that more than 800 plants are used as
traditional remedies for the treatment of diabetes
(Pushparaj et al. 2000; Alarcon-Aguilara et al. 1998),
but only a few have received scientific scrutiny.
Adenanthera pavonina Linn. (Family: Leguminosae-
Mimosaceae), is a deciduous tree, 18–24 m tall, bole erect
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and 60 cm in diameter (Bouquet and Debray 1974).
Many species of adenanthera, including Adenanthera
pavonina, have been used as traditional herbal medicine
against a variety of diseases including diabetes, lipid
disorders, diarrhoea, haemorrhage from the stomach,
haematuria and as anti-inflammatory agent in gout.
The seed contains an anti-inflammatory active principle,
O-acetylethanolamine. The leaves contain octacosanol,
dulcitol, glucosides of betasitosterol and stigmasterol.
The bark contains sitgmasterol glucoside (Khare 2007).
Traditionally, the ground seed is widely used for the
treatment of various human ailments such as treatment
of boils, inflammation, blood disorders, arthritis, rheu-
matism, cholera, paralysis, epilepsy, convulsion, spasm
and indigestion (Burkill 1966; Balogun and Fetuga
2004). Phytochemically, the seed and pod contain glyco-
sides, saponins and steroids (Howes 1974; Yadav et al.
1976). A new five-membered lactone ring compound,
pavonin was isolated from the methanol soluble part of
A. pavonina (S.A.Muhammad et al. 2005), oil extracted
from the seed has been reported to have membrane-
stabilizing activity by reducing lytic effect on erythro-
cytes, exhibited by many intravenous drugs (Anna et al.
2006). The methanol seed extract has also been reported
to demonstrate anti-inflammatory and analgesic activities
(Olajide et al. 2004).
On the basis of reported activities and chemical constit-
uents the aqueous extract of seed was chosen. Therefore,
taking into consideration the reported pharmacological ac-
tivities of Adenanthera pavonina Linn. the present study is
planned to investigate antihyperglycaemic and lipid lower-
ing potential in Stz- induced diabetic rats.
Materials and methods
Plant material
Seeds of Adenanthera pavonina were collected during
March 2009 from the Mahatma Phule Krishi Vidyapeeth,
Rahuri, Maharashtra, India. The plant was authenticated by
Dr. P.G. Diwakar, Joint Director, Botanical Survey of India,
Pune as Adenanthera pavonina Linn. (Mimosaceae) with a
voucher specimen (BSI/WRC/Tech/2010/463) kept in her-
barium, BSI, Pune.
Preparation of extract
The seeds were washed with distilled water, shed dried and
latter powdered. This powder was then defatted with petro-
leum ether which was further macerated with distilled water
for 72 h with occasional shaking. It was then filtered and
evaporated. The yield of APSAE was 2.5 % w/w.
Preliminary phytochemical screening
The preliminary phytochemical screening of APSAE was
carried out for qualitative identification of type of phytocon-
stituents present (Latha and Pari 2004; Kokate 1994).
Animals
Healthy adult male wistar rats weighing 150-200 g and
Swiss albino mice weighing 25–30 g were obtained from
in house breed at the animal house of M.E.S. College of
Pharmacy, Sonai and were housed in polypropylene cages
lined with husk in standard environmental conditions (Tem-
perature 25±2°C; relative humidity 55±10 %; and 12:12
light: dark cycle,). The animals were fed on a standard
pellet diet (Amrut rat and mice feed, Sangli, India) and
water ad libitum.
Animals were acclimatized to the laboratory condition
for at least 8 days prior to the experiment and were main-
tained in a well ventilated animal house. The experimental
protocol was approved by the Institutional animal Ethical
Committee (MESCOP/IAEC/07/2010) and the care of the
laboratory animals was taken as per the current CPCSEA
regulation.
Experimental design
Acute toxicity study (OECD 425, 2001)
Acute toxicity of APSAE was done using Swiss albino mice
(25–30 g) according to the procedure of Organization for
Economic Co-operation and Development (OECD) guide-
line no. 425 (OECD, 2001). The animals were fasted
overnight prior to the experiment and maintained under
standard conditions. Animals were observed for general
behavioral change and mortality for a period of 14 days
post treatment.
Effect of APSAE on normoglycaemic rats
The rats were divided into four groups of 6 animals (n06)
each. Group I served as control and received distilled water.
Group II, III and IV received APSAE orally at doses 50,100
and 200 mg/kg/day b.wt. Blood glucose levels were deter-
mined at 0,1,2,3 and 4 h following treatment by retro-orbital
plexus of the eye under mild ether anesthesia.
Oral glucose tolerance test in normal rats (OGTT)
The rats were divided into four groups of 6 animals (n06)
each. Group I served as control and received distilled water.
Group II, III and IV received APSAE orally at doses 50,100
and 200 mg/kg/day b.wt. All the animals were given glucose
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(2 g/kg) 30 min after dosing. Blood samples were collected
from the retro-orbital plexus of the eye just prior (0 h) and 1,
2, 3 and 4 h. after the glucose loading and blood glucose
levels were estimated.
Induction of diabetes
Diabetes was induced in rats by single intraperitoneal
injection of STZ (55 mg/kg b.wt.) dissolved in freshly
prepared 0.01 M citrate buffer, pH 4.5. (Gupta et al.
2004) after 72 h rats with marked hyperglycemia (fast-
ing blood glucose ≥250 mg/dl) were selected and used
for the study.
Treatment schedule
Total of 36 Wistar rats were used (30 Diabetic surviv-
ing and 06 nondiabetics). The rats were divided into
six groups of 6 animals (n06) each as follows- The
solution of APSAE was prepared with 1 % gum acacia,
an emulsifying agent. Glibenclamide was served as a
reference standard. Group-I (Nondiabetic Control) ani-
mals were received only 1 % gum acacia (1 ml/kg/day,
p.o.). Group-II (Diabetic Control) animals were diabet-
ic and received 1 % gum acacia (1 ml/kg/day, p.o.).
Group-III (Diabetic +Glibenclamide) animals were
diabetic and received glibenclamide (0.25 mg/kg/day,
p.o.) (Sun Pharmaceuticals Ltd, India). Groups IV, V,
VI animals were diabetic and received three different
doses of APSAE 50, 100 and 200 mg/kg, p.o. respec-
tively. All the animals received above treatment for
30 days.
Evaluation of antihyperglycaemic activity
Antihyperglycaemic activity of APSAE was evaluated by
estimation of blood glucose levels and body weight mea-
surement on 1st, 10th, 20th and 30th day of the study by
the glucose oxidase/peroxidase (GOD/POD) (Trinder
1969) method using a standard kit obtained from Span
Diagnostics, India.
Evaluation of antihyperlipidaemic activity
At the end of the experiment, the animals from each group
were sacrificed by cervical dislocation and blood and organs
were collected to estimate various biochemical and histolog-
ical studies (Chakrabarti et al. 2005). Blood was collected
from the heart and allowed to clot and the serumwas separated
by centrifuged at 3,500 rpm for 10 min. Serum was assayed
either immediately or stored at -20°C. The tissue like pancreas
was collected and used for histological studies. Serum
Table 1 Effect of APSAE on
blood glucose level (BGL) of
normoglycaemic rats
*P<0.05, **P<0.01 Values are
Mean±SEM, n06, when com-
pared with normal by using one
way ANOVA followed by Dun-
nette’s multiple comparison test
Group Treatment (n06) Fasting plasma glucose level (mg/dl) at (hrs)
0 1 2 3 4
I Normal 94.00±0.36 94.16±0.30 91.50±0.76 91.16±0.47 91.66±0.33
II Glibenclamide 93.83±0.30 93.50±0.22 90.33 ±0.71 88.83±0.40* 88.00±0.44**
III APSAE 93.66±0.33 93.33±0.21 92.00±0.36 91.16±0.30 90.66±0.21
IVAPSAE 94.33±0.33 94.00±0.36 91.66±0.66 90.66±0.49 90.16±0.30*
VAPSAE 94.16±0.98 93.83±0.40 90.50±0.42 90.16±0.30 89.83±0.40**
Table 2 Effect of APSAE on
oral glucose tolerance test in
STZ-induced diabetic rats
(OGTT)
*P<0.05, **P<0.01 Values are
Mean±SEM, n06, when
compared with diabetic control
by using one way ANOVA




Fasting plasma glucose level (mg/dl) at (hrs)
0 1 2 3 4
I Normal 101.17±1.66 126.17±1.95 136.50±1.05 146.00±0.68 155.17±0.65
II Diabetic control 258.00±1.06 268.33±1.25 280.17±1.24 290.00±0.96 299.00±0.5
III Diabetic+
glibenclamide
257.67±1.22 267.00±1.12 277.00±0.96 284.17±1.01* 265.67±0.49**
IV Diabetic+APSAE 259.50±1.05 269.33±1.14 279.00±0.96 289.00±0.96 274.17±1.16*
V Diabetic+APSAE 257.67±0.84 268.00±0.93 277.17±1.01 287.33±0.66 270.83±1.49*
VI Diabetic+APSAE 260.17±0.60 270.17±0.60 276.67±0.61 284.83±0.47* 266.17±0.47**
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samples were analyzed spectrophotometrically for triglycer-
ides, total cholesterol, high density lipoprotein (HDL-C), us-
ing their respective kits UV- visible spectrophotometer (Jasco
V-630, Japan), VLDL-C and LDL-C were calculated as per
Friedwald’s equation (Richterich and Colmbo 1981).
VLDL¼TG=5; LDL¼TC HDLþVLDLð Þ.
(Alayash et al. 1988; Burstein et al. 1970; Friedwald et al.
1972).
Estimation of glycated hemoglobin
After 30 days of treatment, the 12 h fasted rats were
sacrificed by cervical decapitation, blood was withdrawn
by retro orbital puncture under light ether anesthesia
and the glycated hemoglobin was estimated (Sadasivam
and Manickam 1996).
Statistical analysis
The results were expressed as mean±S.E.M., statistical dif-
ference was doone by using one-way analysis of varience
(ANOVA) followed by Dunnette’s multiple comparison test.




The study showed the presence of steroids, terpenoids,
alkaloids, tannins, phenolic compounds, flavonoids, Sugars
and amino acids.
Acute toxicity study
Oral administration of APSAE was found safe up to dose of
2,000 mg/kg, p.o. produced no signs of toxicity. However,
from 5 g/kg APSAE caused slow movement of animal,
decreased aggressiveness, altered touch and pain sensibility
but did not cause any negative behavioral changes such as
excitement, respiratory distress, convulsions or coma. No
mortality was observed up to 14 days. Hence, the median
lethal dose (LD50) of the APSAE was then greater than
2,000 mg/kg body weight. Therefore doses 50,100 and
200 mg/kg b.wt. were selected for all in vivo experiments.
Effect of APSAE in normoglycaemic rats
The results from the study exhibited that there was no
significant effect observed on normoglycaemic rats when
Table 3 Antihyperglycaemic
effect of APSAE on blood glu-
cose level (BGL) of STZ-
induced diabetic rats
*P<0.05, **P<0.01 Values are
Mean±SEM, n06, when com-
pared with diabetic control by
using one way ANOVA fol-
lowed by Dunnette’s multiple
comparison test
Group Treatment (n06) Fasting plasma glucose concentration (mg/dl) at
1st day 10th day 20th day 30th day
I Normal 98.66±3.94 101.50±4.54 101.17±5.30 103.17±4.57
II Diabetic control 277.83±1.50 372.17±7.90 398.50±6.28 413.33±2.80
III Diabetic+glibenclamide 295.17±1.37 154.67±10.19** 126.67±1.70** 106.33±1.28**
IV Diabetic+APSAE 302.17±1.74 174.33±3.29* 141.67±1.70* 125.83±0.60*
V Diabetic+APSAE 300.83±1.53 169.50±4.40* 138.33±1.94* 118.00±0.57**
VI Diabetic+APSAE 302.50±4.54 163.83±3.68* 127.33±1.58** 113.00±1.03**
Table 4 Effect of APSAE on serum lipid profile in STZ-induced diabetic rats
Group Treatment (n06) Body Cholesterol LDL HDL VLDL Triglycerides
in (mg/dl)
I Normal 66.83±0.47 23.33±0.42 11.50±0.42 16.66±0.30 66.00±0.57
II Diabetic control 94.00±0.73 95.50±0.76 8.00±0.51 23.00±0.36 113.17±0.60
III Diabetic+glibenclamide 69.66±0.49** 36.83±0.60** 12.16±0.30** 17.83±0.65** 75.50±0.76**
IV Diabetic+APSAE 81.16±0.47* 53.16±0.47** 12.33±0.33** 20.33±0.42* 82.50±0.76**
V Diabetic+APSAE 77.00±0.57** 46.66±0.49** 13.33±0.33** 18.83±0.40** 79.50±0.78**
VI Diabetic+APSAE 73.50±0.42** 38.83±0.60** 13.66±0.42** 18.66±0.21** 77.50±0.38**
*P<0.05, **P<0.01 Values are Mean±SEM, n06, when compared with diabetic control by using one way ANOVA followed by Dunnette’s
multiple comparison test
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treated with the single dose of APSAE at 50,100 and
200 mg/kg b.wt. (Table 1).
Oral glucose tolerance test in normal rats (OGTT)
The results from the study indicated that the APSAE at 50,100
and 200 mg/kg and glibenclamide (0.25 mg/kg) reduced the
blood glucose level (hyperglycemia due to glucose load 2 g/kg
p.o.) significantly after 3 h of oral administration, when com-
pared to diabetic control group (Table 2).
Antihyperglycaemic activity
The results from the repeated administration of APSAE
daily up to 30 days exhibited significant antihyperglycaemic
activity in stz-induced diabetic rats, whilst there was no
significant effect observed on normoglycaemic rats. How-
ever, at the end of 30 days of treatment, there was a 74.27 %,
69.55 %, 71.45 % and 72.66 % (p<0.01) decrease of serum
glucose levels with the glibenclamide and APSAE (50,100
and 200 mg/kg) respectively when compared with diabetic
control group (Table 3).
Antihyperlipidaemic activity
The results from the repeated administration of APSAE
daily up to 30 days exhibited significant reduction in lipid
profile in stz-induced diabetic rats. Lipid profile of
animals showed significant reductions (p<0.01) of
13.82 %, 18.08 % and 22.34 % CHL (cholesterol),
44.21 %, 51.57 % and 60.00 % LDL, 11.60 %,
18.13 % and 18.86 % VLDL (Very Low density lip-
oproteins) and 27.43 %, 30.08 % and 31.85 % TG after
treatment with APSAE 50,100 and 200 mg/kg respec-
tively when compared with diabetic control rats. There
was also a significant (p<0.01) increase of 54.12 %,
66.62 % and 70.75 % HDL in the APSAE treated
diabetic rats in comparison of diabetic control rats,
where a fall in HDL level (Table 4).
Changes in body weight
At the end of 30 days treatment, the body weight of normal
rats, APSAE and standard drug treated group, increased
significantly, whereas body weight of diabetic control group
decreased (Table 5).
Changes of serum glycosylated hemoglobin
After 30 days of treatment with APSAE, it was observed
that animals treated with APSAE showed a significant de-
crease in glycosylated hemoglobin levels when compared to
diabetic control groups (Table 6).
Discussion
The use of traditional medicine and medicinal plants in most
developing countries, as a normative basis for the mainte-
nance of good health has been widely observed (Tiwari and
Madhusudanarao 2002). Diabetes mellitus is probably the
fastest growing metabolic disease in the world and as
knowledge of the heterogeneous nature of the disease
increases so does the need for more challenging and appro-
priate therapies. Traditional plant remedies have been used
Table 5 Effect of APSAE on
body weight in STZ-induced di-
abetic rats
*P<0.05, **P<0.01 Values are
Mean±SEM, n06, when com-
pared with diabetic control by
using one way ANOVA fol-
lowed by Dunnette’s multiple
comparison test
Group Treatment (n06) Changes in body weight (gm) at
1st day 10th day 20th day 30th day
I Normal 160.00±0.83 167.00±0.85 176.50±0.76 185.50±0.76
II Diabetic control 161.17±0.94 155.33±1.30 149.83±1.13 140.17±1.77
III Diabetic+glibenclamide 159.50±1.89 163.50±1.23* 170.50±0.61** 179.17±0.70**
IV Diabetic+APSAE 159.83±2.07 163.67±1.87* 169.67±0.98** 176.50±0.84**
V Diabetic+APSAE 158.67±5.04 165.17±1.62* 171.73±1.25** 177.83±0.79**
VI Diabetic+APSAE 159.17±1.13 166.67±0.84* 173.17±1.13** 180.33±0.76**
Table 6 Effect of APSAE on glycosylated Hb and change in body
weights of normal and diabetic rats
Group Treatment (n06) HbA1c mg/gm Hb
I Normal 6.45±0.17





*P<0.05, **P<0.01 Values are Mean±SEM, n06, when compared
with diabetic control by using one way ANOVA followed by Dun-
nette’s multiple comparison test
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for centuries in the treatment of diabetes (Akhtar and Ali
1984; Kesari et al. 2005; 2007; Rai et al. 2007), but only a
few have been scientifically evaluated. Therefore, we have
investigated the effect of Adenanthera pavonina seed aque-
ous extract on glycemic control and serum lipid profile in
STZ-induced diabetic rats. APSAE showed a dose depen-
dent effect on fasting blood glucose at 50,100 and 200 mg/
kg b.wt. in diabetic rats. So, detailed studies were carried out
with the dose of 50,100 and 200 mg APSAE mg/kg b.wt.
The capacity of APSAE to decrease the elevated blood
glucose to normal level is an essential trigger for the liver
to revert to its normal homeostasis during experimental
diabetes. Lower levels of total hemoglobin observed in
diabetic rats might be due to the increased formation of
HbA1c. In uncontrolled or poorly controlled diabetes, there
is an increased glycosylation of a number of proteins in-
cluding hemoglobin and crystalline of lens (Alberti and
Keen 1982). HbA1c was found to increase in patients with
diabetes mellitus and the amount of increase was directly
proportional to the fasting blood glucose levels (Pari and
Saravanan 2002) therefore, measurement of HbA1c is sup-
posed to be very sensitive index for glycemic control. Treat-
ment with APSAE showed a significant decrease in the
glycated hemoglobin levels, which could be due to an
improvement in insulin secretion. Induction of diabetes with
STZ is associated with the characteristic loss of body
weight, which is due to increased muscle wasting (Swan-
ston-Flatt et al. 1990), and due to loss of tissue proteins
(Chatterjea and Shinde 1976). Diabetic rats treated with the
APSAE showed an increase in body weight when compared
to the untreated diabetic rats which may be due to its
protective effect in controlling muscle wasting i.e. reversal
of gluconeogenesis and may also be due to the improvement
in glycemic control. Increased levels of triglycerides and
cholesterol during diabetes lead to cardiovascular complica-
tions. In this study, STZ-induced diabetic mellitus charac-
terized by hyperglycemia caused a significant rise in serum
lipids. These findings indicate that diabetes mellitus is ac-
companied by increased risk of atherosclerosis and coronary
artery diseases. Lowering of serum lipid levels through
dietary or drug therapy seems to be associated with a de-
crease in the risk of vascular disease (Rhoads et al. 1976). In
the present study, the APSAE significantly reduced the
triglyceride, total cholesterol, LDL and VLDL cholesterol
levels with an increase of HDL cholesterol in treated dia-
betic rats as compared to untreated diabetic rats so, these
changes are could be beneficial in preventing diabetic com-
plications as well as in improving lipid metabolism in dia-
betics (Gupta et al. 2005). The significant control of the
levels of serum lipids in the APSAE treated diabetic rats
could be directly attributed to improvement in glycemic
control upon APSAE therapy. Hence, these findings dem-
onstrate that Adenanthera pavonina could be beneficial to
treat diabetes mellitus and complications owing to its anti-
hyperglycaemic and lipid lowering effect. Further studies
are necessary to substantiate above claim and to work out
exact mechanism of action involved in antihyperglycaemic
and antihyperlipidaemic activity of this plant.
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